Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cansu Karakas

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
American Journal of Clinical Pathology|March 1, 2023
Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer CohortCansu Karakas, Haley Tyburski, Bradley M Turner, et al.
Seminars in Diagnostic Pathology|July 25, 2022
HER2-low breast cancers: Current insights and future directionsHuina Zhang, Cansu Karakas, Haley Tyburski, et al.
Investigational New Drugs|May 8, 2015
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancerZahi Mitri, Cansu Karakas, Caimiao Wei, et al.
Human Pathology|November 18, 2023
HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low categoryCansu Karakas, Haley Tyburski, Bradley M Turner, et al.
Archives of Pathology & Laboratory Medicine|November 4, 2025
A Validation Study of an Expanded Description of Glandular (Acinar)/Tubule Formation for the Use of Nottingham Grading System for Invasive Breast Carcinomas Demonstrates Improvement in Concordance for Breast Pathologists and Trainees in PathologyCansu Karakas, Rana A Aldrees, Anas Mohamed, et al.
Breast Cancer Research : BCR|January 1, 2015
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrenceJoseph A Caruso, Cansu Karakas, Jing Zhang, et al.
The American Journal of Pathology|May 17, 2016
Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerCansu Karakas, Anna Biernacka, Tuyen Bui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast CancerIman Doostan, Cansu Karakas, Mehrnoosh Kohansal, et al.
Cancer Research|November 29, 2017
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast CancerJason P W Carey, Cansu Karakas, Tuyen Bui, et al.
Molecular Cancer Therapeutics|October 5, 2023
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung MetastasisAmriti R Lulla, Said Akli, Cansu Karakas, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Pathology|March 1, 2023
Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer CohortCansu Karakas, Haley Tyburski, Bradley M Turner, et al.
Seminars in Diagnostic Pathology|July 25, 2022
HER2-low breast cancers: Current insights and future directionsHuina Zhang, Cansu Karakas, Haley Tyburski, et al.
Investigational New Drugs|May 8, 2015
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancerZahi Mitri, Cansu Karakas, Caimiao Wei, et al.
Human Pathology|November 18, 2023
HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low categoryCansu Karakas, Haley Tyburski, Bradley M Turner, et al.
Archives of Pathology & Laboratory Medicine|November 4, 2025
A Validation Study of an Expanded Description of Glandular (Acinar)/Tubule Formation for the Use of Nottingham Grading System for Invasive Breast Carcinomas Demonstrates Improvement in Concordance for Breast Pathologists and Trainees in PathologyCansu Karakas, Rana A Aldrees, Anas Mohamed, et al.
Breast Cancer Research : BCR|January 1, 2015
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrenceJoseph A Caruso, Cansu Karakas, Jing Zhang, et al.
The American Journal of Pathology|May 17, 2016
Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerCansu Karakas, Anna Biernacka, Tuyen Bui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast CancerIman Doostan, Cansu Karakas, Mehrnoosh Kohansal, et al.
Cancer Research|November 29, 2017
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast CancerJason P W Carey, Cansu Karakas, Tuyen Bui, et al.
Molecular Cancer Therapeutics|October 5, 2023
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung MetastasisAmriti R Lulla, Said Akli, Cansu Karakas, et al.
Pageof 4